Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19564481 | 0.86 | HCRTR1 (0.45) | ALDH1A1KDM4ETP53HTTCA12 | |
| SCHEMBL8576590 | 0.86 | HPGD (0.47) | GABRA1GABRB2ALDH1A1KDM4ETSHR | |
| SCHEMBL8542328 | 0.84 | ALDH1A1 (0.40) | GABRA1GABRB2CLCN2ALDH1A1KDM4E | |
| SCHEMBL12680316 | 0.82 | ALDH1A1 (0.42) | GABRA1GABRB2ALDH1A1KDM4EHSD11B1 | |
| SCHEMBL11664523 | 0.82 | LIPG (0.49) | ALDH1A1TSHRMAPK1TP53CA12 | |
| SCHEMBL15445468 | 0.82 | ELANE (0.47) | ALDH1A1KDM4ETSHRMAPK1L3MBTL1 | |
| SCHEMBL32665929 | 0.82 | CES1 (0.47) | GABRA1GABRB2CLCN2KDM4ETSHR | |
| SCHEMBL10717585 | 0.82 | CES1 (0.47) | GABRA1GABRB2CLCN2KDM4ETSHR | |
| SCHEMBL19564480 | 0.81 | HCRTR2 (0.44) | ALDH1A1KDM4EHSD11B1MAPK1L3MBTL1 | |
| SCHEMBL17448849 | 0.81 | TSHR (0.41) | ALDH1A1KDM4ETSHRHIF1AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096618-A1 | A MIXTURE COMPRISING 1,2-ALKANEDIOLS | Symrise AG (DE) | 2022-12-07 | — | — | EP | claimed |
| WO-2022122143-A1 | A MIXTURE COMPRISING 1,2-ALKANEDIOLS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2026-02-19 | — | — | US | disclosed |
| WO-2025051340-A1 | TRPM8 MODULATORS AND RELATED METHOD FOR MODULATING TRPM8 RECEPTORS | SYMRISE AG (DE) | 2025-03-13 | — | — | WO | disclosed |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-31 | — | — | US | disclosed |
| US-10023555-B2 | NSAIDs derivatives and uses thereof | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2018-07-17 | — | — | US | disclosed |
| US-9745284-B2 | 2-pyridyloxy-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2015-12-31 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7226901-B2 | Stable transparent perfuming emulsion | FIRMENICH SA (CH) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | GABRA1 2531/4885GABRB2 1749/4885CLCN2 821/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | GABRA1 4043/4885GABRB2 4062/4885CLCN2 3811/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | GABRA1 4043/4885GABRB2 4062/4885CLCN2 3811/4885 |
| US-10023555-B2 | NSAIDs derivatives and uses thereof | PTGES, PTGES3, PTGS1 | GABRA1 2664/4885GABRB2 2629/4885CLCN2 4109/4885 |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | RBP4, LRAT, RARB | GABRA1 895/4885GABRB2 179/4885CLCN2 4682/4885 |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | PTGES, PTGES3, PTGS1 | GABRA1 2664/4885GABRB2 2629/4885CLCN2 4109/4885 |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | GABRA1 267/4885GABRB2 251/4885CLCN2 1576/4885 |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | RNGTT, NSUN2, POLN | GABRA1 4550/4885GABRB2 4774/4885CLCN2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.